Trial
NCT03994965
The Sub-Sero Study
Phase IIWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
Bjorn H. Ebdrup
Collaborators
Rigshospitalet, Denmark; University of Copenhagen; ACADIA Pharmaceuticals Inc.
Condition
Schizophrenia
Intervention
Pimavanserin 34 milligrams (MG) [Nuplazid]
Why stopped
Drug supply withdrawn (dec 2019)
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-12-09